Capital Research Global Investors Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Capital Research Global Investors lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 85,132,885 shares of the biopharmaceutical company’s stock after buying an additional 8,343,863 shares during the quarter. Gilead Sciences makes up about 1.7% of Capital Research Global Investors’ investment portfolio, making the stock its 11th largest position. Capital Research Global Investors owned about 0.07% of Gilead Sciences worth $5,531,935,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of GILD. Spectrum Asset Management Inc. NB CA grew its stake in Gilead Sciences by 2.2% during the 3rd quarter. Spectrum Asset Management Inc. NB CA now owns 28,726 shares of the biopharmaceutical company’s stock valued at $1,821,000 after acquiring an additional 607 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co acquired a new stake in shares of Gilead Sciences during the third quarter worth approximately $10,711,000. Colony Group LLC boosted its holdings in shares of Gilead Sciences by 4.8% during the third quarter. Colony Group LLC now owns 66,536 shares of the biopharmaceutical company’s stock worth $4,217,000 after purchasing an additional 3,018 shares during the period. Voya Investment Management LLC grew its position in Gilead Sciences by 29.6% during the third quarter. Voya Investment Management LLC now owns 2,436,740 shares of the biopharmaceutical company’s stock valued at $154,441,000 after purchasing an additional 556,936 shares in the last quarter. Finally, Voya Financial Advisors Inc. grew its position in Gilead Sciences by 232.7% during the third quarter. Voya Financial Advisors Inc. now owns 18,224 shares of the biopharmaceutical company’s stock valued at $1,146,000 after purchasing an additional 12,747 shares in the last quarter. Hedge funds and other institutional investors own 80.32% of the company’s stock.

In other news, EVP Brett A. Pletcher sold 2,950 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $75.55, for a total value of $222,872.50. Following the sale, the executive vice president now directly owns 17,594 shares of the company’s stock, valued at $1,329,226.70. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John Francis Cogan sold 2,413 shares of the firm’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $75.27, for a total value of $181,626.51. Following the completion of the sale, the director now directly owns 57,273 shares in the company, valued at $4,310,938.71. The disclosure for this sale can be found here. In the last three months, insiders sold 73,532 shares of company stock worth $5,101,386. Insiders own 0.20% of the company’s stock.

Shares of GILD traded up $2.16 during trading hours on Thursday, hitting $71.82. 634,335 shares of the company were exchanged, compared to its average volume of 30,795,556. The company has a market cap of $91.13 billion, a PE ratio of 17.02, a PEG ratio of 5.79 and a beta of 0.99. The firm’s 50 day moving average is $71.37 and its 200-day moving average is $66.57. Gilead Sciences, Inc. has a 52 week low of $60.89 and a 52 week high of $85.97. The company has a debt-to-equity ratio of 1.02, a quick ratio of 3.01 and a current ratio of 3.10.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.67 by ($0.37). Gilead Sciences had a net margin of 23.99% and a return on equity of 35.49%. The company had revenue of $5.88 billion during the quarter, compared to the consensus estimate of $5.74 billion. During the same period in the previous year, the business posted $1.44 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 6.03 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be issued a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.79%. The ex-dividend date is Thursday, March 12th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.63. Gilead Sciences’s dividend payout ratio (DPR) is 44.30%.

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Gilead Sciences in a research report on Wednesday, February 5th. Sanford C. Bernstein cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $78.00 to $70.00 in a report on Thursday, February 6th. SunTrust Banks reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday. Wells Fargo & Co increased their price objective on Gilead Sciences from $81.00 to $87.00 and gave the stock an “overweight” rating in a report on Wednesday, March 4th. Finally, BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $78.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: Roth IRA

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.